Novel Approach May Prolong Remission After T-Cell Immunotherapy for Leukemia, Lymphoma
Researchers at Seattle Children’s Hospital have launched a first-in-human trial to investigate whether infusions of T-cell antigen–presenting cells prolong the persistence of chimeric antigen receptor T-cell immunotherapy among children with relapsed or refractory acute lymphoblastic leukemia or lymphoma. Dr. Colleen Annesley, oncologist at Seattle Children’s Hospital, and colleagues will conduct the PLAT-03 trial to evaluate the feasibility and safety of antigen–presenting cells designed to reactivate the CAR T-cell response. Annesley discusses the rationale for this study, when she anticipates results and why new treatments are needed to prevent relapses in this patient population.
About Seattle Children’s
Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.
Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.
For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.